1. Search Result
Search Result
Results for "

Smo

" in MedChemExpress (MCE) Product Catalog:

85

Inhibitors & Agonists

1

Screening Libraries

3

Fluorescent Dye

4

Biochemical Assay Reagents

6

Natural
Products

2

Recombinant Proteins

3

Isotope-Labeled Compounds

7

Oligonucleotides

3

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12848
    SAG
    35+ Cited Publications

    Smo Cancer
    SAG is a potent Smoothened (Smo) receptor agonist (EC50=3 nM; Kd=59 nM). SAG activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .
    SAG
  • HY-15108
    Purmorphamine
    20+ Cited Publications

    Organoid Smo Autophagy Neurological Disease Cancer
    Purmorphamine is a smoothened/Smo receptor agonist with an EC50 of 1 μM.
    Purmorphamine
  • HY-17024
    Cyclopamine
    Maximum Cited Publications
    55 Publications Verification

    11-Deoxojervine

    Hedgehog Smo Endogenous Metabolite Cancer
    Cyclopamine is a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay. Cyclopamine is also a selective Smo inhibitor.
    Cyclopamine
  • HY-100224
    SANT-1
    4 Publications Verification

    Smo Hedgehog Cancer
    SANT-1, a potent Smo antagonist, inhibits Hedgehog signaling. SANT-1 shows IC50s of 20 nM and 30 nM in Shh-LIGHT2 and SmoA1-LIGHT2 assay, respectively .
    SANT-1
  • HY-12848B
    SAG hydrochloride
    35+ Cited Publications

    Smo Cancer
    SAG hydrochloride is a potent Smoothened (Smo) receptor agonist (EC50=3 nM; Kd=59 nM). SAG hydrochloride activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .
    SAG hydrochloride
  • HY-16391
    Glasdegib
    5 Publications Verification

    PF-04449913

    Smo Cancer
    Glasdegib (PF-04449913) is a potent and orally bioavailable smoothened inhibitor. Glasdegib (PF-04449913) binds to human SMO (amino acids 181-787) with an IC50 of 4 nM .
    Glasdegib
  • HY-15483
    DY131
    3 Publications Verification

    GSK 9089

    Estrogen Receptor/ERR Smo Endocrinology Cancer
    DY131 (GSK 9089) is a potent and selective ERRγ and ERRβ agonist. DY131displays inactive against ERRα, ERα and ERβ . DY131 also inhibits Smo signaling .
    DY131
  • HY-12316
    20(S)-Hydroxycholesterol
    3 Publications Verification

    20α-Hydroxycholesterol

    Smo Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    20(S)-Hydroxycholesterol (20α-Hydroxycholesterol) is an allosteric activator that selectively targets the Smoothened (Smo) of the Hedgehog pathway with an EC50 of ~30 μM (Hedgehog). 20(S)-Hydroxycholesterol binds to the extracellular cysteine-rich domain (CRD) of Smo in a stereoselective manner, activating downstream Gli transcription factors (without inducing transcription of receptor genes in the Wnt pathway). 20(S)-Hydroxycholesterol enhances osteogenic differentiation of bone marrow stromal cells and synergistically activates the Raf/MEK/ERK pathway with Simvastatin (HY-17502) to promote bone regeneration. 20(S)-Hydroxycholesterol can be used to study the mechanisms of developmental biology, oncology, bone, and angiogenesis .
    20(S)-Hydroxycholesterol
  • HY-16582A
    Sonidegib
    10+ Cited Publications

    EriSmodegib; LDE225; NVP-LDE225

    Smo Cancer
    Sonidegib (Erismodegib) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively .
    Sonidegib
  • HY-12848C
    SAG dihydrochloride
    35+ Cited Publications

    Smo Cancer
    SAG dihydrochloride is a potent Smoothened (Smo) receptor agonist (EC50=3 nM; Kd=59 nM). SAG dihydrochloride activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .
    SAG dihydrochloride
  • HY-N0247
    Saikosaponin B1
    2 Publications Verification

    Hedgehog Smo STAT Interleukin Related TNF Receptor Inflammation/Immunology Cancer
    Saikosaponin B1 is a bioactive constituent of Radix Bupleuri. Saikosaponin B1 is an agonist of the 5-HT2C receptor with an EC50 of 147.41 μM. Saikosaponin B1 inhibits the Hedgehog (Hh) signaling pathway by targeting the transmembrane protein SMO. Sailosaponin B1 can reduce liver fibrosis. Saikosaponin B1 has anti-cancer activities thus can be studies in research for cancers such as Medulloblastoma (MB) .
    Saikosaponin B1
  • HY-16582
    Sonidegib diphosphate
    10+ Cited Publications

    EriSmodegib diphosphate; LDE225 diphosphate; NVP-LDE225 diphosphate

    Smo Cancer
    Sonidegib diphosphate (Erismodegib diphosphate) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively .
    Sonidegib diphosphate
  • HY-13809

    XL-139

    Smo Apoptosis Cancer
    BMS-833923 (XL-139) is an orally biocompatible Smoothened (Smo) inhibitor with anti-tumor activity. It can inhibit the binding of BODIPY cyclopamine to SMO in a dose-dependent manner with an IC50 of 21 nM .
    BMS-833923
  • HY-16587

    IPI-926; Patidegib

    Smo Cancer
    Saridegib is a potent and specific inhibitor of Smoothened (Smo), a key signaling transmembrane protein in the Hedgehog (Hh) pathway.
    Saridegib
  • HY-B0603

    Smo Glucocorticoid Receptor Infection Inflammation/Immunology Endocrinology
    Fluticasone is an inhaled corticosteroid used for respiratory research. Fluticasone is a Smo agonist with an IC50 value of 99 nM. Fluticasone activates Hedgehog signaling and promotes the proliferation of primary neuronal stem or precursor cells .
    Fluticasone
  • HY-19642A
    Glesatinib hydrochloride
    2 Publications Verification

    MGCD265 hydrochloride

    TAM Receptor c-Met/HGFR Cancer
    Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent MET/SMO dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .
    Glesatinib hydrochloride
  • HY-B0877
    Halcinonide
    1 Publications Verification

    SQ-18566

    Smo Caspase RAR/RXR CDK Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Halcinonide (SQ-18566) is an orally active Smoothened (Smo) agonist. Halcinonide activates the Hedgehog signaling pathway by binding to Smo and promoting its internalization and expression, thereby activating Gli transcription factors. Halcinonide not only stimulates cell proliferation, increases the expression of cyclin D2/CDK6 and inhibits the degradation of caspase-3, but also suppresses Bcl-2/Bax-mediated apoptosis, oxidative stress and inflammatory responses. Halcinonide activates RxRγ to upregulate the expression of myelin genes, thereby reducing cerebral infarction and improving behavioral deficits. Halcinonide has been used in studies related to multiple sclerosis and ischemic stroke .
    Halcinonide
  • HY-15412
    HhAntag
    1 Publications Verification

    Smo Cancer
    HhAntag is a specific, potent and orally active small molecule SMO antagonist of the Hh pathway .
    HhAntag
  • HY-100515
    Robotnikinin
    3 Publications Verification

    Hedgehog Inflammation/Immunology
    Robotnikinin is a small molecule capable of binding to and inhibiting the activity of Sonic Hedgehog (Shh) signaling up stream of Smo .
    Robotnikinin
  • HY-12317

    Smo Hedgehog Cancer
    GSA-10 is a potent smooth (Smo) receptor agonist. GSA-10 is a potent osteogenic molecule. GSA-10 can mediate Hedgehog (Hh) signaling. GSA-10 can be used in regenerative medicine for cancer disease and in the study of fat development .
    GSA-10
  • HY-15108G
    Purmorphamine
    1 Publications Verification

    Smo Neurological Disease Cancer
    Purmorphamine (GMP) is Purmorphamine (HY-15108) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Purmorphamine is a smoothened/Smo receptor agonist with an EC50 of 1 μM .
    Purmorphamine
  • HY-100036

    Smo Apoptosis Hedgehog Cancer
    MK-4101 is a Smoothened (SMO) antagonist (IC50 of 1.1 µM for 293 cells ) and also a potent inhibitor of the hedgehog pathway (IC50 of 1.5 µM for mouse cells; IC50 of 1 µM for KYSE180 oesophageal cancer cells). MK-4101 has robust antitumor activity that inhibits tumor cell proliferation and induces extensive apoptosis .
    MK-4101
  • HY-137115

    Smo Cancer
    BODIPY-Cyclopamine is a fluorescently labeled ligand for the Smoothened (SMO) receptor. The activation of SMO is regulated by Patch protein, and over-activated SMO signaling pathways are associated with tumorigenesis. The NanoBRET (Nanofluorescein bioluminescence resonance energy transfer) technique used in the study can sensitively detect the resonance energy transfer between SMO and BODIPY-Cyclopamine, which can be used for high-throughput screening and kinetic analysis. Studying the binding site of BODIPY-Cyclopamine on SMO can also further explore SMO-targeted drugs .
    BODIPY-Cyclopamine
  • HY-12848R

    Smo Reference Standards Cancer
    SAG (Standard) is the analytical standard of SAG. SAG is a potent Smoothened (Smo) receptor agonist (EC50=3 nM; Kd=59 nM). SAG activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .
    SAG (Standard)
  • HY-18636

    NVP-LEQ506

    Smo Cancer
    LEQ506 is a second-generation inhibitor of smoothened (Smo) with IC50s of 2 and 4 nM in human and mouse, respectively.
    LEQ506
  • HY-12848G

    Smo Cancer
    SAG (GMP) is SAG (HY-12848) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. SAG is a potent Smoothened (Smo) receptor agonist (EC50=3 nM; Kd=59 nM). SAG activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .
    SAG
  • HY-177291

    Microsomal Triglyceride Transfer Protein (MTP) Smo Hedgehog LDLR Cardiovascular Disease Cancer
    LAB687 is a microsomal triglyceride transfer protein (MTP) inhibitor with an IC50 of 0.9 nM for apolipoprotein B (apoB) secretion in HepG2 cells. LAB687 also acts as a Smoothened (Smo) antagonist, with IC50 values of 2.48 μM and 3.42 μM against mouse and human Smo receptors, respectively. LAB687 reduces triglyceride and low-density lipoprotein cholesterol (LDL-C) levels, and inhibits the Hedgehog signaling pathway. LAB687 can be used in studies related to Hedgehog-dependent cancers .
    LAB687
  • HY-113965
    CUR61414
    1 Publications Verification

    Hedgehog Smo Apoptosis Inflammation/Immunology
    CUR61414 is a novel, potent and cell permeable Hedgehog signaling pathway inhibitor (IC50 =100-200 nM). CUR61414 is a small-molecule aminoproline class compound and selectively binds to smoothened (Smo) with a Ki value of 44 nM. CUR-61414 can induce apoptosis in cancer cells without affecting neighboring non-tumor cells .
    CUR61414
  • HY-13459

    Smo Cancer
    PF-5274857 is a potent, selective, orally active and brain-penetrant antagonist of Smo, with an IC50 of 5.8 nM and Ki of 4.6 nM. PF-5274857 has potential for research of tumor types including brain tumors and brain metastasis driven by an activated Hh pathway .
    PF-5274857
  • HY-19642

    MGCD265

    TAM Receptor c-Met/HGFR Cancer
    Glesatinib (MGCD265) is an orally active, potent MET/SMO dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .
    Glesatinib
  • HY-100224G

    Smo Hedgehog Cancer
    SANT-1 (GMP) is SANT-1 (HY-100224) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SANT-1, a potent Smo antagonist, inhibits Hedgehog signaling .
    SANT-1
  • HY-110240

    Smo Others
    IHR-1 is a cell membrane impermeable Smo antagonist .
    IHR-1
  • HY-12848A

    Smo Cancer
    (Rac)-SAG is an isoform of SAG (HY-12848). SAG is a potent Smoothened (Smo) receptor agonist (EC50=3 nM; Kd=59 nM). SAG activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .
    (Rac)-SAG
  • HY-120499

    Hedgehog Smo Cancer
    AZD8542 is an antagonist of Smoothened (SMO), playing an important role in oncology. AZD8542 is an Hedgehog (Hh) pathway antagonist on tumor progression with an emphasis on the role of the stroma compartment .
    AZD8542
  • HY-145387

    Smo Cancer
    MRT-81 is a potent antagonist of human and rodent smoothened (Smo) receptors, with an IC50 value of 41 nM in the Shh-light2 cells. MRT-81 has potent hedgehog inhibiting activity. MRT-81 can be used for the research of cancer .
    MRT-81
  • HY-12316R
    20(S)-Hydroxycholesterol (Standard)
    3 Publications Verification

    20α-Hydroxycholesterol (Standard)

    Reference Standards Smo Endogenous Metabolite Cancer
    20(S)-Hydroxycholesterol (Standard) is the analytical standard of 20(S)-Hydroxycholesterol. This product is intended for research and analytical applications. 20(S)-hydroxyCholesterol (20α-Hydroxycholesterol) is an allosteric activator of the oncoprotein smoothened (Smo) that activates the hedgehog (Hh) signaling pathway with an EC50 of 3 μM in a gene transcription reporter assay using NIH3T3 cells .
    20(S)-Hydroxycholesterol (Standard)
  • HY-110326

    Hedgehog Smo Cancer
    Smo antagonist M25 is a smoothened antagonist for inhibition of the hedgehog pathway.
    Smo antagonist M25
  • HY-159893

    Smo Hedgehog Apoptosis Cancer
    SMO-IN-5 ((Compound 25(B31)) is a potent and competitive inhibitor of smoothened (SMO) that can inhibit Hedgehog (Hh) signaling. SMO-IN-5 interacts with Smo through hydrogen bonds, hydrophobic interactions, and electrostatic forces. SMO-IN-5 inhibits PC cell proliferation, migration, and induces apoptosis by suppressing Gli1 expression. SMO-IN-5 exhibits antitumor activity in pancreatic cancer. .
    SMO-IN-5
  • HY-16582AR

    EriSmodegib (Standard); LDE225 (Standard); NVP-LDE225 (Standard)

    Smo Reference Standards Cancer
    Sonidegib (Standard) is the analytical standard of Sonidegib. This product is intended for research and analytical applications. Sonidegib (Erismodegib) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively .
    Sonidegib (Standard)
  • HY-117407

    Smo Cancer
    ALLO-2 is a potent drug-resistant Smoothened (Smo) mutant antagonist that inhibits Smo agonist Hh-Ag1.5-induced luciferase expression in TM3-Gli-Luc cells with IC50 of 6 nM .
    ALLO-2
  • HY-108507

    Smo Cancer
    MRT-10 is a seven-transmembrane receptor smoothened (Smo) antagonist with an IC50 of 0.65 μM in the micromolar range in various Hedgehog (Hh) assays. MRT-10 binds to the Smo receptor at the level of the Bodipycyclopamine binding site. MRT-10 can be used for the research of cancer .
    MRT-10
  • HY-17024R

    11-Deoxojervine (Standard)

    Reference Standards Hedgehog Smo Endogenous Metabolite Cancer
    Cyclopamine (Standard) is the analytical standard of Cyclopamine. This product is intended for research and analytical applications. Cyclopamine is a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay. Cyclopamine is also a selective Smo inhibitor.
    Cyclopamine (Standard)
  • HY-148440

    Hedgehog Smo Cancer
    RL-0070933 is a potent smo cilial modulator with an EC50 value of 0.02 µM. RL-0070933 modulates the translocation and/or accumulation of smoothened to the primary cilia by hedgehog signaling pathway .
    RL-0070933
  • HY-13654

    Smo Hedgehog Cancer
    IPI-269609 is an orally effective Smoothed (SMO) inhibitor that targets the Hedgehog (Hh) signaling pathway. IPI-269609 specifically reduces the ALDH-bright (high aldehyde dehydrogenase activity) cell subset, which is considered the "cancer stem cells" in pancreatic cancer. IPI-269609 significantly inhibits the migration and colony formation of pancreatic cancer cells. IPI-269609 effectively inhibits pancreatic cancer metastasis in a mouse model. IPI-269609 can be used for pancreatic cancer research .
    IPI-269609
  • HY-150564

    Smo Hedgehog Cancer
    SMO-IN-2 is a potent smoothened (SMO) inhibitor with an IC50 value of 123.4 nM for hedgehog (Hh) signaling pathway. SMO-IN-2 has antiproliferative activity against human medulloblastoma cell line Daoy. Anticancer activity .
    SMO-IN-2
  • HY-150567

    Smo Hedgehog Cancer
    SMO-IN-3 (compound 12a) is a potent smoothened (SMO) inhibitor with an IC50 value of 34.09 nM for hedgehog (Hh) signaling pathway. SMO-IN-3 has antiproliferative activity against human medulloblastoma cell line Daoy. Anticancer activity .
    SMO-IN-3
  • HY-147743

    Smo Cancer
    SMO-IN-1 (Compound 15) is an orally active Smoothened (SMO) inhibitor with an EC50 of 89 nM against sonic Hh protein (shh) .
    SMO-IN-1
  • HY-153499

    Smo Cancer
    SMO-IN-4 (Compound 24) is a potent and orally active smoothened antagonist (IC50: 24 nM). SMO-IN-4 has antitumor activity .
    SMO-IN-4
  • HY-RS13442

    Small Interfering RNA (siRNA) Others

    Smo Mouse Pre-designed siRNA Set A contains three designed siRNAs for Smo gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Smo Mouse Pre-designed siRNA Set A
    Smo Mouse Pre-designed siRNA Set A
  • HY-RS13441

    Small Interfering RNA (siRNA) Others

    SMO Human Pre-designed siRNA Set A contains three designed siRNAs for SMO gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SMO Human Pre-designed siRNA Set A
    SMO Human Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: